US 11,912,748 B2
Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
Andrea Mahr, Tuebingen (DE); Toni Weinschenk, Aichwald (DE); Helen Hoerzer, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Dusslingen (DE); and Harpreet Singh, Munich (DE)
Assigned to Immatics Biotechnologies GmbH, (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on May 7, 2021, as Appl. No. 17/314,629.
Application 17/314,629 is a continuation of application No. 16/889,352, filed on Jun. 1, 2020, granted, now 11,230,581.
Application 16/889,352 is a continuation of application No. 15/815,644, filed on Nov. 16, 2017, abandoned.
Application 15/815,644 is a continuation of application No. 15/199,199, filed on Jun. 30, 2016, granted, now 9,908,922, issued on Mar. 6, 2018.
Claims priority of provisional application 62/187,507, filed on Jul. 1, 2015.
Claims priority of application No. 1511546 (GB), filed on Jul. 1, 2015.
Prior Publication US 2021/0277081 A1, Sep. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/47 (2006.01); C07K 14/74 (2006.01); A61K 39/00 (2006.01); C12N 15/115 (2010.01); C07K 7/08 (2006.01); C07K 7/06 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); A61K 35/17 (2015.01); C07K 16/30 (2006.01); C12P 21/02 (2006.01); C12Q 1/6881 (2018.01); G01N 33/569 (2006.01); C07K 14/82 (2006.01); C07K 16/32 (2006.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); C07K 14/705 (2006.01); C07K 16/18 (2006.01); A61K 38/00 (2006.01); A61K 35/12 (2015.01)
CPC C07K 14/4748 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/4705 (2013.01); C07K 14/4738 (2013.01); C07K 14/705 (2013.01); C07K 14/70539 (2013.01); C07K 14/82 (2013.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C07K 16/2833 (2013.01); C07K 16/30 (2013.01); C07K 16/303 (2013.01); C07K 16/3015 (2013.01); C07K 16/3023 (2013.01); C07K 16/3038 (2013.01); C07K 16/3046 (2013.01); C07K 16/3053 (2013.01); C07K 16/3069 (2013.01); C07K 16/32 (2013.01); C12N 5/0636 (2013.01); C12N 15/115 (2013.01); C12P 21/02 (2013.01); C12Q 1/6881 (2013.01); C12Q 1/6886 (2013.01); G01N 33/56977 (2013.01); G01N 33/57449 (2013.01); G01N 33/57492 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); A61K 2035/124 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2319/00 (2013.01); C07K 2319/40 (2013.01); C12N 2310/16 (2013.01); C12N 2320/30 (2013.01); C12N 2501/50 (2013.01); C12N 2501/998 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/70539 (2013.01)] 20 Claims
 
1. A peptide consisting of the amino acid sequence KIFEMLEGV (SEQ ID NO: 11) in the form of a pharmaceutically acceptable salt.